NEW YORK (GenomeWeb News) – Lentigen has licensed an HIV-related lentiviral vector technology patent held by the University of Cambridge, the company said today.
Â
Baltimore-based Lentigen signed an exclusive agreement with Cambridge Enterprise, the technology licensing arm of the University of Cambridge, for technology that was developed by Andrew Lever.
Â
"The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies," said Boro Dropulic, who is Lentigen’s founder, president, and chief scientific officer.
Â
The licensing deal follows the acquisition of Cell Genesys’ lentiviral patent portfolio late last year by GBP Capital, who is Lentigen’s majority shareholder.
Â
Financial terms of the agreement were not released.